Study of IPG1094 Tablets in Chinese Healthy Adults and Obese Adults

Inclusion Criteria:

1. Male and female Chinese participants aged 18-50 years inclusive.
2. Part A/B (healthy adults): Physical examination, vital signs, 12-lead ECG, chest X-ray, laboratory tests are normal or abnormalities considered not clinically significant by investigator; male body weight ≥50.0 kg, female ≥45.0 kg; BMI 19.0-26.0 kg/m².
3. Part C (obese adults): BMI 28.0-35.0 kg/m²; body weight stable within 3 months prior to screening (weight change ≤5%). No concomitant diseases interfering with safety, PK or weight evaluation.
4. Female participants are non-pregnant and non-lactating.
5. All participants (male and female) agree to use effective contraception from informed consent through 6 months after last study drug administration; no plan for pregnancy, sperm / oocyte donation.
6. For Part C: Able to complete hospitalization for first 10 days, outpatient visits, home drug administration and study diary; refrain from additional weight-loss medications, bariatric surgery or intensive weight-loss programs.
7. Voluntarily sign written informed consent form.

Exclusion Criteria:

1. History of severe/uncontrolled cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immune, dermatological, neurological or psychiatric diseases with ongoing clinical significance.
2. ECG: QTcF >450 ms (male) / >470 ms (female).
3. Recurrent headache/migraine, recurrent nausea/vomiting.
4. Blood donation ≥400 mL within 3 months before screening.
5. History of orthostatic hypotension, dysphagia.
6. Gastrointestinal disorders affecting drug absorption.
7. Cannot comply with unified diet requirements, lactose intolerance.
8. Major surgery within 3 months before screening or planned surgery during study.
9. Known hypersensitivity to study drug or placebo excipients.
10. Alcohol or substance abuse history; positive drug-of-abuse screen or positive alcohol breath test.
11. Excessive alcohol / tobacco / caffeine intake defined per protocol.
12. Use of metformin or other biguanides within 3 months before screening; systemic glucocorticoids within 1 month before screening; CYP-modifying drugs within 30 days before screening; prescription/OTC/herbal products within 14 days before screening.
13. Consumption of grapefruit / citrus fruits/juice within 5 days pre-screening and refusal to abstain during study.
14. Vaccines or biological agents within 4 months pre-screening or planned during study.
15. Participation in another interventional clinical trial within 3 months before screening.
16. Difficult venous access, history of needle-phobia.
17. Acute disease within 14 days prior to screening.
18. Other conditions judged inappropriate for enrollment by investigator. Additional Exclusion for Part C (obese participants)： Fasting glucose ≥11.0 mmol/L or HbA1c ≥8.0%; secondary obesity, eating disorders, clinically significant cardiovascular disease, moderate-severe obstructive sleep apnea, active liver disease, significant renal impairment.

Repeated BP: SBP ≥160 mmHg or DBP ≥100 mmHg; ALT/AST >2×ULN; total bilirubin >1.5×ULN; eGFR <60 mL/min/1.73 m².

Weight-loss drugs, intensive weight-loss program within 3-month pre-screening; prior or planned bariatric surgery.